The American Hospital Association has again blasted the drug industry’s alliance with community health centers for 340B reform, calling it “another misguided attempt by drug companies to dismantle [340B] so that they can continue to pad their billion-dollar bottom lines.”
…
Drug maker Novartis told a federal appeals court in Washington, D.C. Tuesday its revised 340B contract pharmacy policy “does not impact the legal arguments at issue” in its 340B contract pharmacy case awaiting the court’s decision.
If the court disagrees,
…
UPDATE Friday, March 31, 2023, 6:45 p.m. EDT—Story updated with comment from the National Association of Community Health Centers.
Drug manufacturer GlaxoSmithKline this afternoon announced a major expansion of its conditions on 340B pricing in the contract
…
Drug manufacturer Pfizer today stiffened its conditions on 340B sales to hospitals of the immunosuppressant Xeljanz, one of its top-selling products.
Starting May 1, Pfizer will let hospitals without an in-house pharmacy designate just one contract pharmacy for Xeljanz. Pfizer
…
ASAP 340B, the nonprofit group that the drug industry and health centers formed to help advance their joint plan to remake the 340B program, has hired an executive director and published an FAQ that responds to questions and criticism. “There
…
AIDS Healthcare Foundation held two demonstrations Tuesday—one outdoors and loud, the other indoors and silent—at the 340B Coalition winter conference in California to protest against the new drug industry/community health center alliance to change the 340B program.
“Let’s be clear.
…
Drug manufacturer AbbVie this morning significantly tightened its restrictions on 340B pricing for hospitals.
AbbVie has not yet responded to a request for comment about the changes. Non-hospital covered entities continue to be exempt from AbbVie’s pricing restrictions.
Drug manufacturers
…
Ryan White Clinics for 340B Access has announced it opposes the drug industry’s joint plan with community health centers to restructure the 340B program, saying it will increase manufacturers’ “already astronomical profits at the expense of safety net providers.”
Hemophilia
…
A confidential document composed by Pharmaceutical Research and Manufacturers of America in connection with its 340B program reform initiative with the National Association of Community Health Centers fleshes out a “coalition” vision of the 10-point reform plan that the two
…*Sign up for news summaries and alerts from 340B Report